U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07323095) titled 'Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia' on Dec. 08, 2025.
Brief Summary: This is a phase 2, international, multicenter, randomized, double blind, parallel group trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 28
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Chronic Kidney Disease
Intervention:
DRUG: ABP-671 plus febuxostat Group 1
...